secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2026-01-29T23:59:59+00:00
Accession:  0001193125-26-028228
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health reports positive 6-month Revita data; 70% weight regain reduction in key subgroup
--------------------------------------------------------------------------------

- Revita-treated patients (n=40) had 4.5% weight regain vs 7.5% sham at 6 months (p=0.07) in REMAIN-1 Midpoint Cohort.
- In above-median GLP-1 weight loss subgroup, Revita achieved 70% relative reduction in weight regain vs sham (p=0.004).
- Revita improved cardiometabolic markers: HDL +15.5 vs +3.9 mg/dL (p=0.01) and reduced sweet-food cravings (p=0.04).
- No serious adverse events related to Revita; no study discontinuations due to adverse events through 6 months.
- Fractyl requested FDA feedback on De Novo reclassification for Revita; feedback expected Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526028228/0001193125-26-028228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526028228/guts-20260129.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-028228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer